Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The present study was undertaken to investigate thoroughly the preclinical psychopharmacological profile of venlafaxine, testing a wide range of doses in animal models indicative of antidepressant-like effects. Venlafaxine was found to be active in mouse forced swimming test (at 8, 16, 32 and 64 mg/kg) and to increase spontaneous locomotor activity (at 16, 32 and 64 mg/kg). Venlafaxine antagonised apomorphine-induced (16 mg/kg) hypothermia (at 2, 4, 8, 16, 32 and 64 mg/kg). Pretreatment with PCPA significantly attenuated the anti-immobility effects of venlafaxine (8 and 16mg/kg; P< 0.01) in the mouse forced swimming test. Venlafaxine at a dose of 32 mg/kg remained active, despite PCPA pretreatment. DSP-4 significantly attenuated the anti-immobility effects of venlafaxine (16 mg/kg; P < 0.05), whereas venlafaxine at 32 mg/kg remained active, despite DSP-4 pretreatment. Venlafaxine was active in the forced swimming test when administered at sub-effective doses in combination with (+/-) pindolol (venlafaxine: 1 and 2 mg/kg), RU 24969 (venlafaxine: 1, 2 and 4 mg/kg), 8-OH-DPAT (venlafaxine: 4 mg/kg), clonidine (venlafaxine: 1, 2 and 4 mg/kg), lithium (venlafaxine: 1, 2, and 4 mg/kg) and quinine (venlafaxine: 1 and 2 mg/kg). Prior administration with NAN-190 antagonised the anti-immobility effects of venlafaxine (8, 16 and 32 mg/kg). Interaction studies did not induce changes in locomotor activity. The results of the present study indicated that, at low doses, venlafaxine inhibited serotonin reuptake, while at higher doses it inhibited both serotonin and noradrenaline reuptake.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Venlafaxine’s effect on noradrenaline reuptake is dose-dependent, starting on doses of around 225 mg daily. When the daily dose is lower, it acts on serotonin reuptake only, like a common SSRI [36, 37].”
From Treatment of trauma-affected refugees with venlafaxine versus sertraline combined with psychotherapy - a randomised study (2016) · cites this paper as [37]
In the citing paper
“Venlafaxine is a phenylethylamine derivative inhibiting the reuptake of serotonin/5-HT; norepinephrine/NE; and to a lesser extent dopamine/DA (Bolden-Watson and Richelson, 1993; Redrobe et al., 1998).”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Redrobe et al., 1998
Citations
Cites
Behavioral despair in mice: a primary screening test for antidepressants.
Porsolt, R. D., Bertin, A., & Jalfre, M. (1977) · PubMed · Cited by 4,063
Tricklebank, M. D., Forler, C., & Fozard, J. R. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90714-3 · Cited by 675 · cited 2×
“E⁄ects include hypothermia in both mice and rats (Goodwin et al. 1985; Hjorth 1985), a characteristic i5-HT syndromei in rats ( Tricklebank et al. 1984 ) and alterations in rat feeding behaviour (Hutson et al. 1988).”
BackgroundPRESYNAPTIC RECEPTORS AND THEIR ROLE IN THE REGULATION OF TRANSMITTER RELEASE.
Langer, S. Z. (1977) · Cited by 611
Functional Correlates of Serotonin 5-HT1Recognition Sites
Hoyer, D. (1988) · Journal of Receptor Research · doi:10.3109/10799898809048978 · Cited by 562 · cited 2×
“In addition to its ability to bind to 5-HT1A receptors (Hoyer 1988) and antagonise the postsynaptic behavioural e¤ects of 8-OHDPAT (Tricklebank et al. 1987; Lucki 1989), pindolol also acts as an antagonist at presynaptic 5-HT1A receptor sites (Lucki 1992).”
BackgroundMuth, E. A., Haskins, J. T., Moyer, J. A., Husbands, G. E. M., Nielsen, S. T., & Sigg, E. B. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90769-0 · Cited by 374 · cited 2×
“Venlafaxine has not been shown to inhibit monoamine oxidase (Muth et al. 1986).”
BackgroundResult5-Hydroxytryptamine Receptor Subtypes
Peroutka, S. J. (1988) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.11.030188.000401 · Cited by 358
Behavioural despair in mice : A primary screening test for antidepressants
Porsalt, R. D. (1977) · Medical Entomology and Zoology · Cited by 332
Goodwin, G. M., De Souza, R. J., & Green, A. R. (1985) · Neuropharmacology · doi:10.1016/0028-3908(85)90153-4 · Cited by 252 · cited 1×
“E¤ects include hypothermia in both mice and rats (Goodwin et al. 1985; Hjorth 1985), a characteristic 5-HT syndrome in rats (Tricklebank et al. 1984) and alterations in rat feeding behaviour (Hutson et al. 1988).”
BackgroundHypothermia in the rat induced by the potent serotoninergic agent 8-OH-DPAT
Hjorth, S. (1985) · Journal of Neural Transmission · doi:10.1007/bf01253058 · Cited by 241
Glennon, R. A., Naiman, N. A., Pierson, M. E., Titeler, M., Lyon, R. A., & Weisberg, E. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90212-9 · Cited by 184 · cited 2×
“NAN 190 is an arylpiperazine derivative which has a high a¦nity for the 5-HT1A receptor and it has been shown to act as a 5-HT1A antagonist in vivo (Glennon et al. 1988; Chojnacka-Wojcik et al. 1991).”
Background
Cited by
Items 101–163 of 163
Chang, H. H., Chou, C., Yang, Y. K., Lee, I. H., & Chen, P. S. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.3.250 · Cited by 28
Artaiz, I., Zazpe, A., Innerárity, A., del Olmo, E., Díaz, Á., Ruíz-Ortega, J. Á., Castro, E., Pena, R., Labeaga, L., Pazos, Á., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0087-3 · Cited by 24
“In spite of differences between laboratories, predictive assays of antidepressant activity such as the tail suspension test and the FST in mice are responsive to major classes of antidepressants, including tricyclics, SSRIs and SNRIs (Dalvi and Lucki 1999; Redrobe et al. 1998; Millan et al. 2001b).”
BackgroundMethodInfluentialBen‐Azu, B., Aderibigbe, A. O., Ajayi, A. M., Omogbiya, I. A., Uruaka, C. I., Umukoro, S., & Iwalewa, E. O. (2021) · Nutrire · doi:10.1186/s41110-021-00137-5 · Cited by 24
“Previous studies have shown that consecutive administration of pCPA depletes 5-HT stores and reduces the effect of antidepressant drugs; and thus, serves as a pharmacological tool for elucidating the mechanism of action of compounds that are linked to 5-HT system [11, 37].”
BackgroundYücel, N. T., Evren, A. E., Kandemir, Ü., & Can, Ö. D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221095528 · Cited by 19
“Administration of PCPA (100 mg/kg, four consecutive days) has been shown to reduce endogenous serotonin stores by 60–90% in the CNS of mice without any effect on norepinephrine and dopamine levels (Koe and Weissman, 1966; Redrobe et al., 1998).”
Backgroundda Silva, D. P. B., Florentino, I. F., de Oliveira, L. P., Lino, R. C., Galdino, P. M., Menegatti, R., & Costa, É. A. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.08.008 · Cited by 19
“It is known that the dose of PCPA used in this study is able to deplete about 60% of endogenous storage of serotonin content without altering the noradrenaline or dopamine levels (Fajemiroye et al., 2014b; Redrobe et al., 1998a, 1998b).”
Backgroundde Melo, C. T. V., de Carvalho, A. M. R., Moura, B. A., Teixeira, C. P. L., Vasconcelos, L. F., Feitosa, M. L., de Oliveira, G. V., Barbosa‐Filho, J. M., Gutierrez, S. J. C., Fonteles, M. M. D. F., et al. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00968.x · Cited by 24
Effect of antidepressant drugs on 6-OHDA-treated mice in the FST
Chenu, F., Dailly, É., & Bourin, M. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.04.006 · Cited by 19
Self-citationBicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression
Axford, L. C., Boot, J. R., Hotten, T. M., Keenan, M., Martin, F. M., Milutinovic, S., Moore, N. A., O‘Neill, M. F., Pullar, I. A., Tupper, D. E., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00660-7 · Cited by 20
Thomas, J., Khanam, R., & Vohora, D. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.06.008 · Cited by 18
“We combined low doses of venlafaxinewith agomelatine in an attempt to achieve antidepressant efficacy at much lower doses in two commonly employed behavioural paradigms (FST and TST) in mice.”
MethodInfluentialTokgöz, G., Özkay, Ü. D., Osmaniye, D., Yücel, N. T., Can, Ö. D., & Kaplancıklı, Z. A. (2018) · Molecules · doi:10.3390/molecules23112881 · Cited by 19
Mishra, B. R., Maiti, R., Nath, S., Sahoo, P., Jena, M., & Mishra, A. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001022 · Cited by 17
Shulman, R. B., Scheftner, W. A., & Nayudu, S. K. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00019 · Cited by 16
de Sousa, F. C. F., Oliveira, I. C. M., Silva, M. I. G., de Melo, C. T. V., Santiago, V. R., Chaves, R. D. C., Fernandes, M. L., Gutierrez, S. J. C., Vasconcelos, S. M. M., Macêdo, D. S., et al. (2012) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2012.01069.x · Cited by 18
Thomas, J., Khanam, R., & Vohora, D. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.10.003 · Cited by 15
da Rocha, M. J., Pires, C. S., Presa, M. H., Besckow, E. M., Nunes, G. D., Gomes, C. S., Penteado, F., Lenardao, E. J., Bortolatto, C. F., & Brüning, C. A. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06313-x · Cited by 14
“p-CPA administration reduces the brain levels of 5-HT by about 60% in mice (Redrobe et al. 1998) and the doses and regimen of administration employed in this study were previously shown to completely prevent the antidepressant-like effect of fluoxetine in the mouse FST (Eckeli et al.”
BackgroundMethodBehavioral and Transcriptomic Changes Following Brain-Specific Loss of Noradrenergic Transmission
Isingrini, E., Guinaudie, C., Perret, L. C., Guma, E., Gorgievski, V., Blum, I. D., Colby-Milley, J., Bairachnaya, M., Mella, S., Adamantidis, A., et al. (2023) · Biomolecules · doi:10.3390/biom13030511 · Cited by 18
Alleviation of pain in painful diabetic neuropathy
Tajti, J., Szok, D., Majláth, Z., Csáti, A., Petrovics-Balog, A., & Vécsei, L. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1184648 · Cited by 15
“and norepinephrine reuptake.[77] VEN and desvenlafaxine”
Siddiqui, P. J. A., Khan, A., Uddin, N., Khaliq, S., Rasheed, M., Nawaz, S., Hanif, M., & Dar, A. (2017) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2017.1313697 · Cited by 14
“[53] Redrobe JP, Bourin M, Colombel MC, et al.”
BackgroundRajkumar, R., & Mahesh, R. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777256 · Cited by 15
“The antidepressant-like effects of venlafaxine, an SNRI, are likely to involve 5-HT1B receptors [256].”
BackgroundMoreira, L. K. D. S., de Brito, A. F., da Silva, D. M., Siqueira, L., da Silva, D. P. B., Cardoso, C. S., Florentino, I. F., Galdino, P. M., Ghedini, P. C., Menegatti, R., et al. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113066 · Cited by 13
Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis
Katzman, M. A., Wang, X., Wajsbrot, D., & Boucher, M. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119896066 · Cited by 14
“However, in the clinical setting (Redrobe et al., 1998), some patients may benefit from an increased dose.”
BackgroundOtero, M. D. C., Pérez-Caballero, L., Suárez‐Pereira, I., Hidalgo‐Figueroa, M., Delgado-Sequera, A., Montesinos, J. M., Berrocoso, E., & Martín‐Banderas, L. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125692 · Cited by 15
Balfour, J. A. B., & Jarvis, B. (2000) · CNS Drugs · doi:10.2165/00023210-200014060-00006 · Cited by 16
“[37]”
BackgroundMethodInfluentialUlak, G., Göçmez, S. S., Erden, F., Tanyerı, P., Utkan, T., Yildiz, F., Mutlu, O., & Gacar, N. (2006) · Drug Development Research · doi:10.1002/ddr.20106 · Cited by 13
Evaluation of venlafaxine on glucose homeostasis and oxidative stress in diabetic mice
Khanam, R., Najfi, H., Akhtar, M., & Vohora, D. (2012) · Human & Experimental Toxicology · doi:10.1177/0960327112446840 · Cited by 11
Saito, N., Itoga, M., Minakawa, S., & Kayaba, H. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s300517 · Cited by 12
“Those doses of both drugs are generally considered insufficient for the treatment of depression,(29,30) especially for venlafaxine, which at a dose of 75 mg/day only exerts effects as an SSRI.(31) However, in our experience, patients with multiple symptoms who visit the psychosomatic unit are often oversensitive to si…”
BackgroundVenlafaxine Attenuated the Cognitive and Memory Deficit in Mice Exposed to Isoflurane Alone
Li, L., & Zhang, C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.591223 · Cited by 12
“Another study found that venlafaxine exerted stimulant effect on mouse activity in a locomotor test from the dose of 16 mg/kg (33).”
BackgroundSingh, M. P., & Singh, K. P. (2013) · National Academy Science Letters · doi:10.1007/s40009-012-0110-2 · Cited by 10
Lima, E. B. C., de Sousa, C. N. S., Meneses, L. N., Pereira, Y. F. E. S., Matos, N. C. B., de Freitas, R. B., Lima, N. B. C., Patrocínio, M. C. A., Leal, L. K. A. M., Viana, G. S. D. B., et al. (2016) · Journal of Natural Medicines · doi:10.1007/s11418-016-1053-6 · Cited by 10
Ratajczak, P., Kus, K., Skurzyńska, M., & Nowakowska, E. (2017) · Human & Experimental Toxicology · doi:10.1177/0960327117747023 · Cited by 10
“Similar results in several independent studies were obtained by Nowakowska et al.26–28 Study by Redrobe et al.29 has also proven reduced IT upon single VEN administration at the doses of 8, 16, 32 and 64 mg/kg of body weight.”
MethodPresa, M. H., da Rocha, M. J., Pires, C. S., Ledebuhr, K. N. B., da Costa, G. P., Alves, D. A. C., Bortolatto, C. F., & Brüning, C. A. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00108 · Cited by 8
Neuropharmacological assessment in mice and molecular docking of piperazine derivative LQFM212
Moreira, L. K. D. S., de Brito, A. F., Fontana, C., de Carvalho, F. S., Sanz, G., Vaz, B. G., Lião, L. M., da Rocha, F. F., Verli, H., Menegatti, R., et al. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112827 · Cited by 9
22-azidosalvinorin A exhibits antidepressant-like effect in mice
Fajemiroye, J. O., Polepally, P. R., da Cunha, L. C., Costa, É. A., & Zjawiony, J. K. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.02.031 · Cited by 8
Stimulus properties of venlafaxine in a conditioned taste aversion procedure
Kayır, H., ALICI, T., Göktalay, G., Yildirim, M., Ulusoy, K. G., Ceyhan, M., Çelik, T., & Uzbay, T. I. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.08.015 · Cited by 7
“Moreover, venlafaxine has also been dose-dependently active in various animal models of depression (Llyod et al., 1992; Redrobe et al., 1998).”
BackgroundZhang, G., Zhang, Y., Yang, J.-X., Hu, M. S., Zhang, Y., & Liang, X. (2012) · PubMed Central · doi:10.3969/j.issn.1673-5374.2012.14.011 · Cited by 7
“These drugs are reported to be superior to conventional selective serotonin reuptake inhibitors, especially for severe depression([17-19]).”
BackgroundStimulant use in patients presenting with psychocutaneous disorders
Richey, P. M., Laageide, L. G., & Swick, B. L. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.04.033 · Cited by 6
Yao, J.-Q., Liu, C., Jin, Z., Liu, Y., Yin, Y., Fang, X., Ran, Y., Zhang, L., & Li, Y. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108230 · Cited by 5
In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor
Hou, J., Xing, Y., Zuo, D., Wu, Y., Tian, J., Meng, Q., & Yang, M. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.10.007 · Cited by 6
Moharir, S., Akotkar, L., Aswar, U. M., Kumar, D., Gawade, B., Pal, K., & Rane, R. (2024) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00870-4 · Cited by 4
“The forced swim test (FST) was performed to evaluate the antidepressant activity of the test compounds, with reduction in immobility time considered an antidepressant activity of the drugs [25].”
Warren, K., & Solomon, I. C. (2012) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2012.07.004 · Cited by 4
A review on animal models of depression.
Parle, M., & Dhingra, S. (2010) · Asian Journal of Biological Sciences · Cited by 3
Magalhães, L. S., Strelow, D. N., Paim, M. P., Rech, T. D. S. T., Krüger, L. D., Braga, A. L., Neto, J. S. S., Brüning, C. A., & Bortolatto, C. F. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173651 · Cited by 3
Venlafaxin ist kein SSRI, sondern ein SNRI, und das ist relevant
Fritze, J., Schneider, B., & Weber, B. (2003) · psychoneuro · doi:10.1055/s-2003-39633 · Cited by 2
“bei höherer Dosis von Venlafaxin kommt zur serotonergen Wirkung die noradrenerge hinzu (24).”
Lindauer, A. (2011) · bonndoc (University of Bonn) · Cited by 2
Barhoma, M., Carlsson, J., & Sonne, C. (2024) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2024.2324357 · Cited by 1
Mandujano, J. L., & Eugenia, S. (2012) · InTech eBooks · doi:10.5772/32593 · Cited by 2
Behavioral and transcriptomic changes following brain-specific loss of noradrenergic transmissionPreprint
Isingrini, E., Guinaudie, C., Perret, L. C., Guma, E., Gorgievski, V., Blum, I. D., Colby-Milley, J., Bairachnaya, M., Mella, S., Adamantidis, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.12.523778 · Cited by 2
“Here, we reported anxiolytic and antidepressant-like effects of central NE depletion in the FST, marble-burying test, and novelty-suppressed feeding test (Figure 1A–”
InfluentialThe pharmacology of the sigma-1 receptor.
Brimson, J. M. (2010) · The University of Bath Online Publications Store (The University of Bath) · Cited by 2
大木, 雄., オオギ, ユ., & Yuta, O. (2013) · Institutional Repositories DataBase (IRDB)
Mahesh, R., Bhatt, S., Devadoss, T., Jindal, A., Gautam, B., Dhar, A. K., & Pandey, D. K. (2013)
de Médecine, F., Doctorale, É., & Biologie, C. (2003)
Screening Models of Depression in Animals: A Review
Singh, R., Semwal, A., & Kakar, S. (2013) · Pharmacologia · doi:10.5567/pharmacologia.2013.343.348
Hascoët, M., & Bourin, M. (2011) · Neuromethods · doi:10.1007/978-1-61779-313-4_8 · Cited by 4
Self-citationMagalas, Z., & Wagner, H. (2006) · RWTH Publications (RWTH Aachen)
LES RECEPTEURS 5-HT1B : IMPLICATION DANS LE MECANISME D'ACTION DES ANTIDEPRESSEURS
Pharmacie, F. D. (2006)
Marsh, W. (2007) · Elsevier eBooks · doi:10.1016/b978-008055232-3.62846-6 · Cited by 4
Effect of SSRI on C-Reactive Protein in Case of Depression
Chatterjee, S., Debnath, S., Sur, A., Sinha, S., & Chakraborty, I. (2023) · Indian Journal of Public Health Research & Development · doi:10.37506/ijphrd.v14i3.19412
Chattopadhyay, S., Debnath, S., Ray, S., & Sinha, S. (2023) · Indian Journal of Public Health Research & Development · doi:10.37506/ijphrd.v14i3.19427
Ripoll, N. (2005) · OpenGrey (Institut de l'Information Scientifique et Technique)
Coutens, B. (2022) · theses.fr (ABES) · doi:10.70675/7ffbfd7ezefb5z4e4ez82f4z42a6ac0ff754 · Cited by 1
Kandemir, Ü., Sağlik, G. T., Osmaniye, D., Kaplancıklı, Z. A., Can, Ö. D., & Özkay, Ü. D. (2026) · Pharmaceuticals · doi:10.3390/ph19050797
Metadata
- Authors
- Redrobe, J. P., Bourin, M., Colombel, M. C., & Baker, G. B.
- Affiliations
- Nantes Université (FR)
- Venue
- Psychopharmacology
- Published
- 1998-07-01
- Volume
- 138
- Issue
- 1
- Pages
- 1-8
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2037662525
- Cited by
- 163
- References
- 24
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 7 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 7 · 2016: 9 · 2015: 8 · 2014: 7 · 2013: 9 · 2012: 11
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- venlafaxine, antidepressant effects, serotonin reuptake inhibition, norepinephrine reuptake inhibition, dose-dependent effects, forced swim test, immobility, locomotor activity, NAN-190, p-chlorophenylalanine, DSP-4, pindolol, RU 24969, 8-OH-DPAT, clonidine, lithium, quinine
- MeSH terms
- Venlafaxine Hydrochloride, Animals, Cyclohexanols, Male, Motor Activity, Pindolol, Piperazines, Selective Serotonin Reuptake Inhibitors, 8-Hydroxy-2-(di-n-propylamino)tetralin, Antidepressive Agents, Second-Generation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.